Last reviewed · How we verify

SG — Competitive Intelligence Brief

SG (SG) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Adenosine 2A receptor antagonist. Area: Oncology.

marketed Adenosine 2A receptor antagonist A2A receptor (adenosine 2A receptor) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

SG (SG) — Arcus Biosciences, Inc.. SG is an adenosine 2A receptor antagonist that blocks immunosuppressive signaling in the tumor microenvironment to enhance anti-tumor immunity.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
SG TARGET SG Arcus Biosciences, Inc. marketed Adenosine 2A receptor antagonist A2A receptor (adenosine 2A receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Adenosine 2A receptor antagonist class)

  1. Arcus Biosciences, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SG — Competitive Intelligence Brief. https://druglandscape.com/ci/sg. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: